UDENYCA (pegfilgrastim-cbqv)
Chemotherapy-induced Neutropenia
ApprovedCommercial
Key Facts
About Coherus BioSciences
Coherus BioSciences has successfully pivoted from a pure-play biosimilar company to an integrated oncology firm with a dual revenue and R&D strategy. Its commercial biosimilars (UDENYCA®, YUSIMRY™) provide a cash-generative foundation, while its innovative immuno-oncology pipeline, anchored by the approved anti-PD-1 therapy LOQTORZI® (toripalimab) and novel candidates like tagmokitug (anti-CCR8) and casdozokitug (anti-IL-27), targets significant market opportunities in oncology. The company's strategy is to leverage its commercial infrastructure and regulatory expertise to efficiently advance combination therapies that overcome immune resistance.
View full company profileTherapeutic Areas
Other Chemotherapy-induced Neutropenia Drugs
| Drug | Company | Phase |
|---|---|---|
| BBT-015 | Bolder Biotechnology | Preclinical |
| Biosimilar Portfolio (e.g., Filgrastim) | Emcure Pharmaceuticals | Commercial |
| Bmab 1100 (Pegfilgrastim biosimilar) | Biocon | Approved |
| Ziextenzo (pegfilgrastim) | Sandoz Group | Marketed |
| Biosimilar Pegfilgrastim | Viatris | Launched |
| ROLVEDON | Assertio Holdings | Approved |